Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
Abstract: The present invention relates to a liquid crystal panel, a liquid crystal display device and to a liquid crystal medium having a negative dielectric anisotropy ??.
Type:
Grant
Filed:
October 31, 2011
Date of Patent:
March 13, 2018
Assignee:
MERCK PATENT GMBH
Inventors:
Eun-Kyu Lee, Seung-Eun Lee, Dong-Mee Song
Abstract: The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.
Inventors:
Cameron James Smith, John Qiang Tan, Ting Zhang, James Balkovec, William John Greenlee, Liangqin Guo, Yi-Heng Chen, Yili Chen, Samuel Chackalamannil, Tomokazu Hirabayashi, Mika Sekioka
Abstract: The present application relates to an electronic device comprising a hole-transport layer A, a doped hole-transport layer B and a hole-transport layer C, where hole-transport layers A, B and C are arranged between the anode and the emitting layer, and where hole-transport layer B is arranged on the cathode side of hole-transport layer A and hole-transport layer C is arranged on the cathode side of hole-transport layer B.
Type:
Grant
Filed:
September 11, 2013
Date of Patent:
March 13, 2018
Assignee:
Merck Patent GmbH
Inventors:
Frank Voges, Jonas Valentin Kroeber, Christof Pflumm, Joachim Kaiser, Arne Buesing
Abstract: The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
Type:
Grant
Filed:
March 23, 2015
Date of Patent:
March 13, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Helen Mitchell, Mark E. Fraley, Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Casey C. McComas, Kathy Schirripa, Melody McWherter, Ping Liu, Dann Parker, Chun Sing Li, Qinghua Mao
Abstract: The present invention relates compounds comprising a tetra-heteroaryl indacenodithiophene-based structural unit, the synthesis of such compounds as well as their use in organic electronic devices. The invention further relates to organic electronic devices comprising such compounds.
Type:
Grant
Filed:
June 26, 2015
Date of Patent:
March 13, 2018
Assignee:
Merck Patent GmbH
Inventors:
William Mitchell, Mansoor D'Lavari, Changsheng Wang, David Sparrowe
Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
Type:
Grant
Filed:
June 14, 2013
Date of Patent:
March 13, 2018
Assignee:
Merck Patent GmbH
Inventors:
Kevin Adlem, Owain Llyr Parri, Rachel Tuffin, Patricia Eileen Saxton, Benjamin Snow, Mark John Goulding, Nathan Smith
Abstract: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
Type:
Grant
Filed:
December 1, 2016
Date of Patent:
March 13, 2018
Assignees:
Bionomics Limited, Merck Patent GmbH
Inventors:
Andrew Harvey, Agnes Bombrun, Rachel Cooke, Isabelle Jeanclaude-Etter, Nathan Kuchel, Jerome Molette, Jorgen Mould, Dharam Paul, Rajinder Singh, Cristina Donini, Veronique Colovray, Thomas Avery, Julia Crossman, Justin Ripper
Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
Type:
Application
Filed:
November 9, 2017
Publication date:
March 8, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
John Y.L. CHUNG, Kevin CAMPOS, Edward CLEATOR, Robert F. DUNN, Andrew GIBSON, R. Scott HOERRNER, Stephen KEEN, Dave LIEBERMAN, Zhuqing LIU, Joseph LYNCH, Kevin M. MALONEY, Feng XU, Nobuyoshi YASUDA, Naoki YOSHIKAWA, Yong-Li ZHONG
Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
Type:
Application
Filed:
September 25, 2017
Publication date:
March 8, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Petr Vachal, Izzat Raheem, Zhiqiang Guo, Timothy John Hartingh
Abstract: The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that may be useful as synthetic intermediates in the process of the invention.
Inventors:
Hongming Li, Jingjun Yin, Kevin M. Belyk, Kevin R. Campos, Qinghao Chen, Alan M. Hyde, Tetsuji Itoh, Artis Klapars, Matthew Thomas Tudge, Edward Cleator, Aaron M. Dumas, Louis-Charles Campeau, Yonggang Chen, Ji Qi, Wensong Xiao
Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
Type:
Application
Filed:
November 20, 2017
Publication date:
March 8, 2018
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
Abstract: The present invention relates to metal complexes having a metal atom of groups 13 to 15 and at least one ligand, where the ligand comprises at least one anionic coordination group having at least one oxygen and/or nitrogen atom via which the metal atom is coordinated, and the ligand comprises at least one triarylamine group, to processes for preparation thereof and to the use thereof in electronic devices, especially in organic electroluminescent devices, called OLEDs (OLED=organic light emitting diode). The present invention also further relates to organic electroluminescent devices comprising these metal complexes.
Type:
Application
Filed:
April 19, 2016
Publication date:
March 8, 2018
Applicant:
MERCK PATENT GMBH
Inventors:
Philipp Stoessel, Dominik Joosten, Beate Burkhart, Katja Stegmaier
Abstract: Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
Abstract: The present invention relates to alkaline earth aluminate phosphors, to a process for the preparation thereof and to the use thereof as conversion phosphors. The present invention also relates to an emission-converting material comprising at least the conversion phosphor according to the invention, and to the use thereof in light sources, in particular pc-LEDs (phosphor converted light emitting devices). The present invention furthermore relates to light sources, in particular pc-LEDs, and to lighting units which comprise a primary light source and the emission-converting material according to the invention.
Type:
Application
Filed:
March 2, 2016
Publication date:
March 8, 2018
Applicant:
MERCK PATENT GMBH
Inventors:
Aleksander ZYCH, Mathias RAPPHAHN, Ralf PETRY, Ingo KOEHLER, Andreas BENKER, Stefan TEWS
Abstract: The present invention provides compounds of Formula (I) for the treatment of parasitic diseases including malaria, as well as neurodegenerative diseases. Formula (I) wherein R3, R4, X and Y have the meaning given in claim 1.
Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.
Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
Type:
Grant
Filed:
October 19, 2012
Date of Patent:
March 6, 2018
Assignees:
THE NETHERLANDS CANCER INSTITUTE, MERCK SHARP & DOHME CORP.
Inventors:
HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
Abstract: The present invention relates to interference pigments based on multicoated flake-form substrates which have on the surface of the substrate a layer sequence comprising (A0) optionally a high-refractive-index coating consisting of a layer of TiO2, (A) a high-refractive-index coating consisting of a mixture of TiO2 and Fe2O3, which may optionally be doped with one or more further oxides, (B) a high-refractive-index layer consisting of SnO2, (C) a high-refractive-index coating which absorbs in the visible wavelength region, and optionally (D) an outer protective layer, and to the use thereof, in particular in paints, coatings, industrial coatings, automobile paints, automotive refinish paints, coil coating, powder coatings, printing inks, plastics, pigment pastes, pigment preparations and in dry preparations, such as, for example, granules.
Abstract: Claimed is a cyclometallated organometallic light emitting complex having two tridentate ligand portions sharing a central heterocycle “A” providing a binding-site for each of the two metals (formula I): Formula (I): A more illustrative embodiment is formula (XII): Characterizing for the invention is that either one of XI and X2 and either one of Y1 and Y2 is carbon. The dinuclear complexes are for use in OLEDs.